CureVac Sustainability Profile
CureVac AG, a pioneering biopharmaceutical company headquartered in Tübingen, Germany, is at the forefront of mRNA technology. Founded in 2000, CureVac has made significant strides in the development of innovative therapies and vaccines, particularly in the fields of oncology and infectious diseases. The company is renowned for its proprietary mRNA platform, which enables the creation of targeted treatments that harness the body’s own immune response. Notable achievements include the advancement of its COVID-19 vaccine candidate, which showcased the potential of mRNA in rapid vaccine development. With a strong market position, CureVac continues to expand its operational reach across Europe and North America, solidifying its role as a leader in the biopharmaceutical industry.
DitchCarbon Score
How does CureVac's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
CureVac's score of 22 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
CureVac's reported carbon emissions
CureVac, headquartered in Germany (DE), currently does not report any specific carbon emissions data, as there are no available figures for kg CO2e emissions. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. As of now, CureVac has not cascaded any emissions data from a parent or related organization, indicating that their climate commitments and emissions reporting are independent. Without specific emissions data or reduction initiatives, it is unclear how CureVac is addressing its carbon footprint or contributing to climate action within the biopharmaceutical industry. In the absence of concrete figures or targets, it is essential for CureVac to establish clear climate commitments and reduction strategies to align with industry standards and expectations for sustainability.
How Carbon Intensive is CureVac's Industry?
How Carbon Intensive is CureVac's Location?
CureVac's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
CureVac has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
